PMID- 29178674
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 2092-7355 (Print)
IS  - 2092-7363 (Electronic)
IS  - 2092-7355 (Linking)
VI  - 10
IP  - 1
DP  - 2018 Jan
TI  - A Retrospective Study of Clinical Response Predictors in Subcutaneous Allergen 
      Immunotherapy With House Dust Mites for Allergic Rhinitis.
PG  - 18-24
LID - 10.4168/aair.2018.10.1.18 [doi]
AB  - PURPOSE: House dust mites (HDM) are major allergens that cause allergic rhinitis 
      (AR). Allergen-specific subcutaneous immunotherapy (SCIT) has been shown to be 
      clinically beneficial in many clinical trials. Such trials, however, are not 
      reflective of all patient populations. The aim of this study was to describe the 
      efficacy and safety of SCIT in routine clinical practice in Korean adults with AR 
      sensitized to HDM. METHODS: We reviewed medical records of 304 patients with AR 
      treated at an allergy clinic of a tertiary hospital using SCIT with aluminum 
      hydroxide-adsorbed allergen extract targeting HDM alone or with pollens for at 
      least 1 year from 2000 to 2012. Patients with asthma were excluded. Rates of 
      remission, defined as no further requirement of maintenance medication, over time 
      were determined by means of life tables and extension of survival analysis. 
      Specific immunoglobulin E (IgE) levels to HDM were categorized into 6 classes. 
      RESULTS: The mean time until achieving remission was 4.9+/-0.1 years, and the 
      cumulative incidence of remission from AR was 76.6%. Severe AR (odds ratio [OR], 
      0.40; 95% confidence interval [CI], 0.23-0.69; P=0.001), specific IgE levels to 
      HDM >/=17.5 kU/L (OR, 1.85; 95% CI, 1.01-3.37; P=0.045), and duration of 
      immunotherapy >/=3 years (OR, 7.37; 95% CI, 3.50-15.51; P<0.001) were identified as 
      significant predictors of clinical remission during SCIT for patients with AR 
      sensitized to HDM. Overall, 73 patients (24.0%) experienced adverse reactions to 
      SCIT, and only 1 case of anaphylaxis (0.3%) developed. CONCLUSIONS: SCIT with HDM 
      was found to be effective and safe for patients with AR. Specific IgE levels to 
      HDM and a duration of SCIT >/=3 years may be predictors of clinical responses to 
      SCIT in AR patients.
CI  - Copyright (c) 2018 The Korean Academy of Asthma, Allergy and Clinical Immunology . 
      The Korean Academy of Pediatric Allergy and Respiratory Disease
FAU - Lee, Ji Ho
AU  - Lee JH
AD  - Department of Allergy and Clinical Immunology, Ajou University School of 
      Medicine, Suwon, Korea.
FAU - Kim, Su Chin
AU  - Kim SC
AD  - Clinical Trial Center, Ajou University Medical Center, Suwon, Korea.
FAU - Choi, Hyunna
AU  - Choi H
AD  - Clinical Trial Center, Ajou University Medical Center, Suwon, Korea.
FAU - Jung, Chang Gyu
AU  - Jung CG
AD  - Department of Allergy and Clinical Immunology, Ajou University School of 
      Medicine, Suwon, Korea.
FAU - Ban, Ga Young
AU  - Ban GY
AD  - Department of Allergy and Clinical Immunology, Ajou University School of 
      Medicine, Suwon, Korea.
FAU - Shin, Yoo Seob
AU  - Shin YS
AD  - Department of Allergy and Clinical Immunology, Ajou University School of 
      Medicine, Suwon, Korea.
FAU - Nahm, Dong Ho
AU  - Nahm DH
AD  - Department of Allergy and Clinical Immunology, Ajou University School of 
      Medicine, Suwon, Korea.
FAU - Park, Hae Sim
AU  - Park HS
AD  - Department of Allergy and Clinical Immunology, Ajou University School of 
      Medicine, Suwon, Korea.
FAU - Ye, Young Min
AU  - Ye YM
AD  - Department of Allergy and Clinical Immunology, Ajou University School of 
      Medicine, Suwon, Korea. ye9007@ajou.ac.kr.
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - Allergy Asthma Immunol Res
JT  - Allergy, asthma & immunology research
JID - 101518382
PMC - PMC5705479
OTO - NOTNLM
OT  - Allergen-specific immunotherapy
OT  - house dust mites
OT  - remission
OT  - rhinitis, allergic
COIS- There are no financial or other issues that might lead to conflict of interest.
EDAT- 2017/11/28 06:00
MHDA- 2017/11/28 06:01
PMCR- 2018/01/01
CRDT- 2017/11/28 06:00
PHST- 2017/05/01 00:00 [received]
PHST- 2017/07/12 00:00 [revised]
PHST- 2017/07/25 00:00 [accepted]
PHST- 2017/11/28 06:00 [entrez]
PHST- 2017/11/28 06:00 [pubmed]
PHST- 2017/11/28 06:01 [medline]
PHST- 2018/01/01 00:00 [pmc-release]
AID - 10.18 [pii]
AID - 10.4168/aair.2018.10.1.18 [doi]
PST - ppublish
SO  - Allergy Asthma Immunol Res. 2018 Jan;10(1):18-24. doi: 10.4168/aair.2018.10.1.18.